Total Valuation
Arovella Therapeutics Limited has a market cap or net worth of €45.59M. The enterprise value is €60.24.
Market Cap€45.59M
Enterprise Value€60.24
Share Statistics
Arovella Therapeutics Limited has 1,208,851,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,208,851,800
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Arovella Therapeutics Limited’s return on equity (ROE) is -0.49 and return on invested capital (ROIC) is -52.55%.
Return on Equity (ROE)-0.49
Return on Assets (ROA)-0.46
Return on Invested Capital (ROIC)-52.55%
Return on Capital Employed (ROCE)-0.79
Revenue Per Employee0.00
Profits Per Employee-256.16K
Employee Count27
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Arovella Therapeutics Limited is ―. Arovella Therapeutics Limited’s PEG ratio is 0.73.
PE Ratio―
PS Ratio0.00
PB Ratio5.26
Price to Fair Value5.26
Price to FCF-10.72
Price to Operating Cash Flow-10.45
PEG Ratio0.73
Income Statement
In the last 12 months, Arovella Therapeutics Limited had revenue of 0.00 and earned -6.92M in profits. Earnings per share was >-0.01.
Revenue0.00
Gross Profit-117.71K
Operating Income-11.21M
Pretax Income-10.41M
Net Income-6.92M
EBITDA-11.10M
Earnings Per Share (EPS)>-0.01
Cash Flow
In the last 12 months, operating cash flow was -6.91M and capital expenditures -39.26K, giving a free cash flow of -6.95M billion.
Operating Cash Flow-6.91M
Free Cash Flow-6.95M
Free Cash Flow per Share>-0.01
Dividends & Yields
Arovella Therapeutics Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.10
52-Week Price Change-12.20%
50-Day Moving Average0.04
200-Day Moving Average0.04
Relative Strength Index (RSI)50.49
Average Volume (3m)0.00
Important Dates
Arovella Therapeutics Limited upcoming earnings date is Sep 2, 2026, TBA (Confirmed).
Last Earnings DateFeb 19, 2026
Next Earnings DateSep 2, 2026
Ex-Dividend Date―
Financial Position
Arovella Therapeutics Limited as a current ratio of 17.51, with Debt / Equity ratio of 0.00%
Current Ratio17.51
Quick Ratio17.51
Debt to Market Cap0.00
Net Debt to EBITDA1.29
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Arovella Therapeutics Limited has paid -3.50M in taxes.
Income Tax-3.50M
Effective Tax Rate0.34
Enterprise Valuation
Arovella Therapeutics Limited EV to EBITDA ratio is -5.42, with an EV/FCF ratio of -8.66.
EV to Sales0.00
EV to EBITDA-5.42
EV to Free Cash Flow-8.66
EV to Operating Cash Flow-8.71
Balance Sheet
Arovella Therapeutics Limited has €14.35M in cash and marketable securities with €0.00 in debt, giving a net cash position of €14.35M billion.
Cash & Marketable Securities€14.35M
Total Debt€0.00
Net Cash€14.35M
Net Cash Per Share€0.01
Tangible Book Value Per Share€0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Arovella Therapeutics Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-100.00%
EPS Growth Forecast15.00%